CompletedNCT01391403
Artemisinin Added to Risperidone for First-Episode Schizophrenia
About this title
Read the official source — NCT01391403Medication studyAges 18–65China
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- BeijingSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 88
- Sponsor
- Beijing HuiLongGuan Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01391403
- Official title
Show the full official title
A Double-Blind, Randomized, Placebo-Controlled Trial of Artemisinin as an Add-on Therapy to Risperidone in the Treatment of Drug-Naive First-Episode Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Beijing
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Beijing HuiLongGuan Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Artemisinin.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
